REPONEX PHARMACEUTICALS A/S: Financial statements 2017
CVR: 30082346
Source: annual report 2017, Danish Business Authority
01/01/2017 – 31/12/2017
REPONEX PHARMACEUTICALS A/S (CVR 30082346) has filed annual accounts for 2017. In 2017, the company reported a gross profit of DKK -1,266,822 and a net result of DKK -1,576,249 compared with DKK -331,569 the year before. Equity in the 2017 report amounted to DKK 3,653,943. The solvency ratio was 46.3%.
- Gross Profit
- DKK -1,266,822
- Profit/Loss
- DKK -1,576,249
- Equity
- DKK 3,653,943
- Total Assets
- DKK 7,894,905
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2017 | - | -1.3 mio. | -1.6 mio. | 3.7 mio. | - |
| 2016 | - | 242 t. | -332 t. | 5.2 mio. | - |
| 2015 | - | -1.2 mio. | -934 t. | 536 t. | - |
| 2014 | 1 | -34 t. | -683 t. | 1.5 mio. | - |
| 2013 | - | - | 150 t. | 230 t. | - |
Official annual report
Keep an eye on REPONEX PHARMACEUTICALS A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2017
REPONEX PHARMACEUTICALS A/S has published its annual report for 2016. Gross profit came to DKK 241,832, and the net result was DKK -331,569.
As of May 31, 2017, Lisbeth Thyregod has joined the board of directors of REPONEX PHARMACEUTICALS A/S.
About REPONEX PHARMACEUTICALS A/S
REPONEX PHARMACEUTICALS A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2006. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named REPONEX PHARMACEUTICALS ApS and TRIFOILIUM ApS. The management consists of Christian Henrik Tange. The board consists of Christian Vinding Thomsen (chair), Troels Peter Troelsen and Charlotte Pahl. The company is owned by Pharma Equity Group A/S. The company has 2 employees (2026). In 2025, the company reported a gross profit of DKK 0 and a net result of DKK -6,570,000 compared with DKK -11,943,000 the year before. Equity in the 2025 report amounted to DKK 4,645,000.